Author
Amelia Baptista
Bio: Amelia Baptista is an academic researcher from University of Lisbon. The author has contributed to research in topics: Viral load & Placebo. The author has an hindex of 6, co-authored 7 publications receiving 4572 citations.
Topics: Viral load, Placebo, Hepatitis C, Pegylated interferon, Gastrin
Papers
More filters
TL;DR: This research presents a meta-analysis of Anatomia e Istologia Patologica, a large quantity of which has never before been published in a peer-reviewed journal, which aims to provide real-time information about the immune system’s response to disease.
4,655 citations
TL;DR: The authors describe three cases of tamoxifen-associated steatohepatitis, which resulted from a daily dosage of 20 mg used as the adjuvant treatment of breast carcinoma, which became normal after discontinuation of tamxifen.
84 citations
TL;DR: This paper presents a meta-analyses of the prophylactic and morphological properties of E.T Roskams’ determinants of liver disease, which have changed since their discovery in the 1950s and are now known as “Roskams-Thaler disease”.
Abstract: T Roskams, A Baptista, L Bianchi, A Burt, F Callea, H Denk, J De Groote, V Desmet, S Hubscher, K Ishak, R MacSween, B Portmann, H Poulson, P Scheuer, L Terracciano & H Thaler Department of Pathology, K.U. Leuven, Leuven, Belgium, Hospital de Santa Maria, Lisboa, Portugal, University of Basel, Basel, Switzerland, University of Newcastle, Newcastle, UK, Spedali Civili of Brescia, Brescia, Italy, University of Graz, Graz, Austria, Department of Hepatology, K.U. Leuven, Leuven, Belgium, Department of Pathology, University of Birmingham, Birmingham, UK, Armed Forces Institute of Pathology, Washington, DC, USA, Department of Pathology, Western Infirmary, University of Glasgow, Glasgow and Institute of Liver Studies, Kings College Hospital, London, UK, Frederics Berg, Denmark, Department of Pathology, Royal Free Hospital, London, UK, and Wien, Austria
57 citations
TL;DR: The objective was to establish a baseline level of confidence in the ability of a single individual to identify the HBV/Gastrointestinal Pathology checkpoints in mice using a simple, straightforward, and straightforward two-step procedure.
Abstract: H.DENK1, P . J.SCHEUER2, A.BAPTISTA3, L.BIANCH14, F . CALLEA', J.DE GROOTE6, V.J.DESMET7, F.GUDAT4, K.G.ISHAK*, G.KORB9, R. N . M.MACS WEEN' O , M. J . PHILLIPS ' , B.PORTMANN1 2 , H. POULSEN' 3 , M.SCHMIDI4 & H.THALER1' 'Department of Pathology, University of Graz, Austria; 2Liver Pathology Unit, Department of Histopathology, The Royal Free Hospital, London, UK; 3Department of Pathology, University of Lisbon, Portugal; 4Department of Pathology, University of Basel, Switzerland; 'Servizio di Anatomia et lstologia Patologica, Spedali Civili, Brescia, Italy, 6Department of Medicine, University of Leuven, Belgium; 7Department of Pathology, University of Leuven, Belgium; 'Hepatic and Gastrointestinal Pathology. Department of Defense, Armed Forces Institute of Pathology, Washington, USA; 'Department of Pathology, Weiden, Germany; \"Department of Pathology, Western Infirmary, University of Glasgow, UK; \"Department of Pathology, Hospital for Sick Children, University of Toronto, Canada; 121nstitute of Liver Studies, King's College Hospital, London, UK; ' 3Uepurtment of Pathology, Herlev Hospital, University of Copenhagen, Denmark; 14Department of Pathology, University of Zurich, Switzerland; \"Vienna, Austria
50 citations
Journal Article•
TL;DR: A sustained response was observed in 5 of 9 AOB pretreated patients six mo after discontinuation of the 12-mo antiviral therapy, encouraging to conduct more extensive clinical studies combining antioxidant with antiviral treatment in hepatitis C.
Abstract: Background/Aims: Oxidative stress is involved in chronic hepatitis C, and efforts have been made to influence the disease process with antioxidants. The present study evaluates the protective effects of a phenol-rich processed grain food with superoxide-scavenging properties (trade name antioxidant biofactor AOB). Methodology: Thirty patients participated in this placebo-controlled double-blind pilot study. AOB was taken orally by fifteen patients for 3 mo at the recommended daily dose of 3x2 sachets, containing 3g of powder each. Another fifteen patients received a herbal extract with practically no superoxide scavenging properties as a placebo. Oxidative stress biomarkers, aminotransferase levels and viral load were evaluated immediately before and after treatment. Results: AOB treatment considerably improved the antioxidant defenses. Also ALT and AST decreased in 11 of the 15 patients (-11% to -65%, mean -22%, p<0.05). The effects of placebo were not significant. Viral load remained unchanged. Control biopsies were not done after the short interval of 3 mo. There were no adverse effects. After the 3-mo treatment with AOB or placebo, 16 of the 30 patients received conventional antiviral treatment (pegylated interferon alpha and ribavirin). A sustained response was observed in 5 of 9 AOB pretreated patients six mo after discontinuation of the 12-mo antiviral therapy. The 7 patients pretreated with placebo were all non-responders. Conclusions: These preliminary results are encouraging to conduct more extensive clinical studies combining antioxidant with antiviral treatment in hepatitis C.
28 citations
Cited by
More filters
TL;DR: It is shown that a simple index using readily available laboratory results can identify CHC patients with significant fibrosis and cirrhosis with a high degree of accuracy and may decrease the need for staging liver biopsy specimens among patients with CHC.
3,637 citations
TL;DR: There are no systems for grading necroinflammatory activity or for staging fibrosis as exist for various other forms of chronic liver disease and this study proposes a grading and staging system that reflects the unique histological features of nonalcoholic steatohepatitis.
3,553 citations
TL;DR: In conclusion, noninvasive tests can accurately predict hepatic fibrosis and may reduce the need for liver biopsy in the majority of HIV/HCV‐coinfected patients.
3,183 citations
TL;DR: This document has been approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.
3,013 citations
[...]
TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
2,790 citations